ISSAR Pharma

Innovation through

peptide drug

discovery, addressing unmet medical needs.

Our new identity

A Motivation towards Peptide Drug Discovery and changing patients’ lives

Therapeutic Areas

Bringing the best of 25 years of peptide research and development

Dermatology is a specialised branch that deals with research, diagnosis and treatment of conditions associated with the skin.
022
Oncology is the branch of medicine that deals with research, identification, and treatment of cancer.
bigstock-Human-Digestive-System-Anatomy-401600672
It is the field of medicine which deals with the study, diagnosis and treatment of diseases associated with the digestive system.
The WHO and UN have recognized four major musculoskeletal conditions contributing to a major burden on individuals and health care…

Our Brands

Over 2,000,000 scientist hours into new peptide drug development, ISSAR has touched 1,00,000 plus lives

Development Pipeline

Solving the unmet healthcare needs using novel peptide technology

Novoskin®
Vitiligo - Topical

Xylentra®
Wound care - Topical

IS -107
Solid tumors - Injectable

IS - 217
Soriacare®
Psoriasis - Injectable
Topical

ISSAR’S Pre-Clinical
Pipeline

INDIA
INDIA
US FDA
INDIA
US FDA
IBD (Injectable)
Sepsis (Injectable)
Rheumatoid Arthritis
Atopic Dermatitis

Key Milestones

A Motivation towards Peptide Drug Discovery and changing patients’ lives
0
Products Commercialized
0
Patents - Granted
0 +
Drugs In Pipeline -Life To New Drugs
0
Lives Touched -Giving Hope to Lives

About Us

Formed as a company driven by pharmaceutical innovation to address the unmet healthcare needs, ISSAR pharmaceuticals Pvt. Ltd. was founded in 1995 by Mr Ramakrishna Isanaka.

Featured Article

Psoriasis patients undergoing biologic/other systemic therapies may experience mild SARS-CoV-2 infection A recent study published in the ‘Medicina’ Journal by the Multidisciplinary …

CXCL9: A biomarker for Vitiligo activity A recent study published in the ‘Nature’ scientific journal, proposed that the CXCL9 gene is a …

Rheumatoid Arthritis (RA) In a Global Burden of Disease (GBD) study conducted in the year 2010, which studied 291 conditions, Rheumatoid Arthritis …

In The News

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

Cadila acquires skin treatment lotion Melgain from ISSAR Pharma

ISSAR Pharma develops first-ever peptide molecule for skin care

Dr.-Reddys-issar

Dr Reddy’s Laboratories Ltd (DRL) to emerge as one of the top five dermatology companies in India with their recent launch of Melgain licensed by ISSAR PHARMACEUTICALS

Contact Us